How much do you know about Natural Killer/T-Cell Lymphoma (NKTCL)?

• Natural killer/T-cell lymphoma (NKTCL) is a rare and aggressive disease with poor prognosis.
• NKTCL is more prevalent in Asia and Latin America.
• The disease is associated with Epstein-Barr virus (EBV) and aberrant expression of CD21.
• Most tumor cells exhibit a cytotoxic phenotype, characterized by granzyme B and perforin expression.
• Early anthracycline-based chemotherapy resulted in poor outcomes due to intrinsic resistance of NKTCL cells to anthracycline.
• Combined modality therapy and non-anthracycline-based chemotherapy improved clinical outcomes.
• NK cells lack asparagine synthase activity, making neoplasms sensitive to l-asparaginase.
• Allogeneic hematopoietic stem cell transplantation (HSCT) has potential in patients with stage III/IV of the disease and in relapsed cases.
• NKTCL predominantly occurs in extranodal sites, including nasal or paranasal areas.
• The median age at diagnosis is approximately 65 years and there is a male predominance in NKTCL.

Test your knowledge on Natural Killer/T-cell Lymphoma (NKTCL), a rare and aggressive disease with poor prognosis. Discover its prevalence in Asia and Latin America, its association with Epstein-Barr virus (EBV), and the cytotoxic phenotype of tumor cells. Learn about the different treatment options available, including non-anthracycline-based chemotherapy, l-asparaginase, and allogeneic hematopoietic stem cell transplantation (HSCT). Challenge yourself on the extran